2024 ´ëÇÑõ½Ä¾Ë·¹¸£±âÇÐȸ Ãá°èÇмú´ëȸ(2ÀÏÂ÷) : 2024-05-11
±³À°ÀÏÀÚ : 2024-05-11
±³À°Àå¼Ò : ±×·£µå ¿öÄ¿Èú ¼¿ï
±³À°ÁÖÁ¦ : 2024 ´ëÇÑõ½Ä¾Ë·¹¸£±âÇÐȸ Ãá°èÇмú´ëȸ(2ÀÏÂ÷)
ÁÖÃÖ±â°ü : ´ëÇÑõ½Ä¾Ë·¹¸£±âÇÐȸ
´ã´çÀÚ : Á¤ÃáÈñ
¿¬¶ôó : 02-747-0528
À̸ÞÀÏ : kaaaci@naver.com
±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, À̺ñÀÎÈÄ°ú, ÇǺΰú, °¡Á¤ÀÇÇаú
Âü¼®¿¹»óÀÎ : 600¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 18 ½Ã°£ 30ºÐ
¼¼ºÎ¼ö°·á : 140,000¿ø
ºñ°í »çÀüµî·Ï: Àü¹®ÀÇ, ÀϹÝÀÇ, ±³¼ö 10¸¸¿ø, Àü°øÀÇ, ±âŸ 5¸¸¿ø / ´çÀϵî·Ï: Àü¹®ÀÇ, ÀϹÝÀÇ, ±³¼ö 14¸¸¿ø, Àü°øÀÇ, ±âŸ 7¸¸¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 05¿ù 11ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëA 09:00~10:00 Treatable Trait in Asthma Peter Gibson(Monash University, Austrailia)
ÈÞ½Ä 05¿ù 11ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï 10:00~10:20 ÈÞ½Ä ()
±³À°½Ã°£ 05¿ù 11ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëA 10:20~10:50 Novel Mechanisms of Immunotherapy: The Role of EAACI Research and Outreach Biobank Project Milena Sokolowska(University of Zurich, Switzerland)
±³À°½Ã°£ 05¿ù 11ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëA 10:50~11:20 SCIT in Real Life Asli Gelincik(Istanbul University, Turkey )
±³À°½Ã°£ 05¿ù 11ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëA 11:20~11:50 Novel immunotherapy strategies enhancing treatment outcomes ÀÌ»ó¹Î(´Ü±¹ÀÇ´ë)
±³À°½Ã°£ 05¿ù 11ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëB 10:20~10:50 The role of eosinophils in airway diseases: asthma and beyond ±èÁÖÈñ(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 05¿ù 11ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëB 10:50~11:20 Biomarkers of eosinophil activation ±èÈ¿ºó(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 05¿ù 11ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëB 11:20~11:50 Updates in mechanism of hypereosinophilic syndrome °³ëÀ»(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 05¿ù 11ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëC 10:20~10:50 The latest trends in molecular target research for drug development ¹Ú»ó±Ô(¾ÆÁÖÀÇ´ë)
±³À°½Ã°£ 05¿ù 11ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëC 10:50~11:20 Innovation in clinical trials: New strategies for asthma and allergy drug development ¹ÝÁØ¿ì(¿ï»êÀÇ´ë)
±³À°½Ã°£ 05¿ù 11ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëC 11:20~11:50 Regulatory science and drug approval process: Overcoming challenges through global collaboration ½ÅÁÖ¿µ(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 05¿ù 11ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëD 10:20~10:50 Emerging insights into innate immunity in allergic airway inflammation Á¶ÇüÁÖ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 05¿ù 11ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëD 10:50~11:20 Comorbidities of allergic rhinitis (sleep apnea, adenoid hypertrophy, AERD, etc) ±èµ¿±Ô(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 05¿ù 11ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëD 11:20~11:50 Personalized medicine of rhinosinusitis : from current biologics to unmet needs Mitsuhiro Okano(International University of Health and Welfare, Japan)
ÈÞ½Ä 05¿ù 11ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï 11:50~12:00 ÈÞ½Ä ()
±âŸ 05¿ù 11ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëA 12:00~12:50 The Evolution of Chronic Urticaria Care: Emerging Trends and Insights Emek Kocaturk(Koç University, Turkey)
±âŸ 05¿ù 11ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëB 12:00~12:50 Asthma John Blakey(Curtin Medical School, Australia)
±âŸ 05¿ù 11ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëC 12:00~12:50 Immunotherapy Johann Virchow(University Hospital Rostock, Germany)
ÈÞ½Ä 05¿ù 11ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï 12:50~13:30 ÈÞ½Ä ()
±³À°½Ã°£ 05¿ù 11ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëA 13:30~14:30 Angioedema from Bench to Bedside: An Update on the EAACI Knowledge Hub Module Asli Gelincik(Istanbul University, Turkey )
ÈÞ½Ä 05¿ù 11ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï 14:30~14:50 ÈÞ½Ä ()
±³À°½Ã°£ 05¿ù 11ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëA 14:50~15:20 Asthma Management and Environmental Impact Hiromasa Inoue(Kagoshima University, Japan)
±³À°½Ã°£ 05¿ù 11ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëA 15:20~15:50 Air pollution and asthma ±ÇÇõ¼ö(¿ï»êÀÇ´ë)
±³À°½Ã°£ 05¿ù 11ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëA 15:50~16:20 How to mitigate the adverse effects of air pollution on respiratory allergic diseases ¼Û´ëÁø(°í·ÁÀÇ´ë)
±³À°½Ã°£ 05¿ù 11ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëB 14:50~16:20 Intestinal permeability and its correlation with treatable traits and inflammatory markers in severe asthma: the Korean Severe Asthma Registry (KoSAR) data analysis ¹ÚÇÑ±â ¿Ü 9¸í(°æºÏÀÇ´ë ¿Ü 9°÷)
±³À°½Ã°£ 05¿ù 11ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëC 14:50~16:20 A 10-year Longitudinal Analysis of Adult Asthmatics with Obesity Unveils Dual Eosinophilic and Neutrophilic Inflammation ÀüÇö¼· ¿Ü 9¸í(¾ÆÁÖÀÇ´ë ¿Ü 9°÷)
±³À°½Ã°£ 05¿ù 11ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëD 14:50~16:20 Targeted inhibition of m6A demethylase FTO by FB23 attenuates allergic inflammation in the airway epithelium Zexuan Lian ¿Ü 9¸í(Guangzhou Medical University ¿Ü 9°÷)
ÈÞ½Ä 05¿ù 11ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï 16:20~16:30 ÈÞ½Ä ()
±³À°½Ã°£ 05¿ù 11ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëA 16:30~17:00 Upper airway disease: AR/CRS ³ª¹Î¼®(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 05¿ù 11ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëA 17:00~17:30 Lower airway disease: Asthma ¹Ý°¡¿µ(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 05¿ù 11ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëA 17:30~18:00 Allergic skin disease: AD/CU Á¤°æ¿í(¾ÆÁÖÀÇ´ë)
±³À°½Ã°£ 05¿ù 11ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëB 16:30~17:15 Asthma remission during biologics treatment ½É´Ù¿î/¿ì¼º´ë(Àü³²ÀÇ´ë/Ãæ³²ÀÇ´ë)
±³À°½Ã°£ 05¿ù 11ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëB 17:15~18:00 Early dietary interventions for food allergy in children Á¤¹Î¿µ/À±Áö¼±(°í½ÅÀÇ´ë/Áß¾ÓÀÇ´ë)
±³À°½Ã°£ 05¿ù 11ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëC 16:30~17:00 Small airway dysfunction in asthma and COPD Omar Usmani(Imperial College London, UK)
±³À°½Ã°£ 05¿ù 11ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëC 17:00~17:30 Unravelling lung function decline in adults with or without asthma ¹ÚÈï¿ì(¼¿ïÀÇ´ë)
±³À°½Ã°£ 05¿ù 11ÀÏ ±×·£µå ¿öÄ¿Èú ¼¿ï ·ëC 17:30~18:00 Recent findings from COPD cohort studies: Focusing on Korean research ¹®Áö¿ë(ÇѾçÀÇ´ë)